Walleye Capital LLC Purchases 57,413 Shares of Ryan Specialty Holdings, Inc. (NYSE:RYAN)

Walleye Capital LLC grew its stake in shares of Ryan Specialty Holdings, Inc. (NYSE:RYAN - Free Report) by 294.6% in the 3rd quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 76,903 shares of the company's stock after purchasing an additional 57,413 shares during the quarter. Walleye Capital LLC's holdings in Ryan Specialty were worth $5,106,000 as of its most recent SEC filing.

Several other institutional investors also recently made changes to their positions in the stock. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC grew its holdings in Ryan Specialty by 0.4% in the 3rd quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC now owns 262,166 shares of the company's stock worth $17,405,000 after buying an additional 935 shares in the last quarter. FORA Capital LLC lifted its position in Ryan Specialty by 6.0% in the third quarter. FORA Capital LLC now owns 17,618 shares of the company's stock worth $1,170,000 after purchasing an additional 992 shares during the period. Bridgewater Associates LP acquired a new stake in Ryan Specialty in the third quarter worth approximately $1,265,000. FMR LLC lifted its position in Ryan Specialty by 72.3% in the third quarter. FMR LLC now owns 12,875 shares of the company's stock worth $855,000 after purchasing an additional 5,402 shares during the period. Finally, Quantbot Technologies LP lifted its position in Ryan Specialty by 34.8% in the third quarter. Quantbot Technologies LP now owns 107,418 shares of the company's stock worth $7,131,000 after purchasing an additional 27,732 shares during the period. 84.82% of the stock is owned by institutional investors.

Insiders Place Their Bets

In related news, EVP Mark Stephen Katz sold 14,790 shares of Ryan Specialty stock in a transaction on Friday, November 8th. The shares were sold at an average price of $71.39, for a total transaction of $1,055,858.10. Following the completion of the transaction, the executive vice president now owns 12,386 shares of the company's stock, valued at $884,236.54. This trade represents a 54.42 % decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at the SEC website. Also, Director David P. Bolger sold 7,055 shares of the firm's stock in a transaction on Thursday, November 21st. The stock was sold at an average price of $70.88, for a total transaction of $500,058.40. Following the completion of the sale, the director now owns 78,149 shares of the company's stock, valued at $5,539,201.12. The trade was a 8.28 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders own 11.10% of the company's stock.

Analyst Upgrades and Downgrades

A number of equities research analysts have recently commented on the company. BMO Capital Markets upgraded Ryan Specialty from a "market perform" rating to an "outperform" rating and increased their price objective for the company from $65.00 to $75.00 in a research report on Tuesday, September 24th. Wells Fargo & Company increased their price objective on Ryan Specialty from $63.00 to $70.00 and gave the company an "equal weight" rating in a research report on Thursday, October 10th. Barclays increased their price objective on Ryan Specialty from $76.00 to $88.00 and gave the company an "overweight" rating in a research report on Thursday, November 21st. UBS Group upped their price target on shares of Ryan Specialty from $67.00 to $76.00 and gave the stock a "buy" rating in a research note on Tuesday, August 13th. Finally, The Goldman Sachs Group upped their price target on shares of Ryan Specialty from $64.00 to $72.00 and gave the stock a "neutral" rating in a research note on Wednesday, October 9th. One equities research analyst has rated the stock with a sell rating, five have issued a hold rating and five have given a buy rating to the company's stock. According to data from MarketBeat, the company presently has a consensus rating of "Hold" and an average target price of $71.67.

Ryan Specialty Price Performance

Shares of NYSE:RYAN traded down $1.33 during trading on Monday, reaching $74.07. The stock had a trading volume of 669,590 shares, compared to its average volume of 868,293. Ryan Specialty Holdings, Inc. has a 52 week low of $41.49 and a 52 week high of $75.97. The business's 50-day moving average price is $70.23 and its 200 day moving average price is $63.41. The company has a debt-to-equity ratio of 2.40, a current ratio of 1.01 and a quick ratio of 1.01. The stock has a market capitalization of $19.39 billion, a PE ratio of 96.61, a P/E/G ratio of 1.71 and a beta of 0.62.

Ryan Specialty (NYSE:RYAN - Get Free Report) last posted its earnings results on Wednesday, October 30th. The company reported $0.41 earnings per share (EPS) for the quarter, meeting analysts' consensus estimates of $0.41. Ryan Specialty had a net margin of 10.31% and a return on equity of 47.90%. The company had revenue of $604.69 million during the quarter, compared to analysts' expectations of $602.04 million. During the same quarter in the previous year, the company posted $0.32 earnings per share. Ryan Specialty's quarterly revenue was up 20.5% compared to the same quarter last year. As a group, equities analysts predict that Ryan Specialty Holdings, Inc. will post 1.8 earnings per share for the current year.

Ryan Specialty Dividend Announcement

The firm also recently declared a quarterly dividend, which was paid on Tuesday, November 26th. Shareholders of record on Tuesday, November 12th were given a dividend of $0.11 per share. The ex-dividend date was Tuesday, November 12th. This represents a $0.44 annualized dividend and a yield of 0.59%. Ryan Specialty's dividend payout ratio (DPR) is presently 57.14%.

About Ryan Specialty

Ryan Specialty Holdings, Inc operates as a service provider of specialty products and solutions for insurance brokers, agents, and carriers in the United States, Canada, the United Kingdom, Europe, and Singapore. It offers distribution, underwriting, product development, administration, and risk management services by acting as a wholesale broker and a managing underwriter.